Project Details
Description
Abstract
Neurotrophic Factor Signaling in the Pathogenesis of HIV-associated Depression: Cohort and
Mechanistic Studies
Depression in people with HIV is known to worsen HIV outcomes as well as quality of life. Prior
studies have shown Brain Derived Neurotrophic Factor (BDNF) is pivotal in neuron development
and maintenance and important in depression. To better understand the pathophysiology of
depression in HIV, we desire to use proteomics to further study the BDNF pathways in pre-
existing CSF samples from people with HIV and then do a proof-of-concept test in a murine HIV
model of depression.
We have access to cerebrospinal fluid from a cohort of outpatients with HIV collected in a study
of HIV-associated Neurocognitive Disorders with CSF and clinical data collection at 0 and 2
years. The evaluation included neurocognitive testing and depression screening with the center
for epidemiological studies depression (CESD). We plan to do discovery and validation
proteomics with focus in the validation proteomics for the BDNF pathway. We will use a
machine-learning analysis plan comparing our proteomics findings with the CESD generally and
on an item-level basis as well as cognitive evaluations using the NIMH Research Domain
Criteria (RDoC) constructs with focus on Loss, Reward Valuation, and Cognition. We plan to do
this analysis first cross-sectionally and then further validate by comparing longitudinally. We
hypothesize CSF neurotrophic factor BDNF with neuroinflammatory markers are associated
with depressive symptoms; strength of association with depressive symptoms will vary within
RDoC domains with persistent neuroinflammation closely tied to ongoing symptoms.
We plan to use our findings from proteomics in an HIV murine model of depression with focus
on the BDNF pathways. We plan to acquire humanized mice and infect half with HIV. We will
evaluate them for depression and then inject half with a BDNF antagonist and evaluate again
with standard depression testing. We hypothesize the treated mice to exhibit more signs of
depression than untreated mice (less sucrose preference, less social interaction, less immobile
time) as BDNF improves resilience and neuroplasticity.
Successful completion will yield impactful data on the BDNF pathways and could discover
additional targets for treatment of HIV-associated depression.
Status | Finished |
---|---|
Effective start/end date | 9/15/21 → 8/31/23 |
Funding
- National Institute of Mental Health: $227,397.00
- National Institute of Mental Health: $195,616.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.